Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5VJAF)

Drug Name
SB-271046 Drug Info
Synonyms
209481-20-9; SB-271046; SB271046; Sb 271046; 5-chloro-N-(4-methoxy-3-(piperazin-1-yl)phenyl)-3-methylbenzo[b]thiophene-2-sulfonamide; UNII-L3SK5KX24S; L3SK5KX24S; CHEMBL431298; SB-271,046; C20H22ClN3O3S2; 5-Chloro-N-[4-methoxy-3-(1-piperazinyl)phenyl]-3-methylbenzo[b]thiophene-2-sulfonamide; 5-chloro-N-(4-methoxy-3-piperazin-1-ylphenyl)-3-methyl-1-benzothiophene-2-sulfonamide; 5-Chloro-N-(4-methoxy-3-(1-piperazinyl)phenyl)-3-methylbenzo(b)thiophene-2-sulfonamide; AC1NSM3X; GTPL276; SCHEMBL194700; SB271046 HCl; BDBM28583; SB
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5312149
CAS Number
CAS 209481-20-9
TTD Drug ID
DM5VJAF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Dopamine D3 receptor (D3R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cariprazine DMJYDVK Bipolar disorder 6A60 Approved [4]
Pramipexole DMNMW9R Parkinson disease 8A00.0 Approved [5]
Ropinirole DMA6S1D Parkinson disease 8A00.0 Approved [5]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [6]
P2B-001 DM9PVHX Parkinson disease 8A00.0 Phase 3 [7]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [8]
ONC201 DMM5SCF Endometrial cancer 2C76 Phase 2 [9]
TAK-906 DMBQD9H Diabetic gastroparesis DA41.00 Phase 2 [10]
GSK598809 DMGU05N Drug abuse 6C4G.1Z Phase 2 [11]
GSK618334 DMJPXZ4 Drug abuse 6C4G.1Z Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [12]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [13]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [14]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [15]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [14]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [16]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [17]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [13]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [18]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D1 receptor (D1R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Phenyltoloxamine DMKAEQW Allergy 4A80-4A85 Approved [20]
Pergolide DM14MAE Parkinson disease 8A00.0 Approved [5]
Methylergonovine DMBEX4O Spontaneous abortion JA00.0 Approved [21]
Fenoldopam DMFAOKP Hypertension BA00-BA04 Approved [22]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [23]
Ecopipam DMS9R43 Cocaine addiction 6C45.2 Phase 3 [24]
DAS-431 DMM3BPL Dementia 6D80-6D86 Phase 2 [25]
Dihydrexidine DMACPQO Psychotic disorder 6A20-6A25 Phase 1/2 [26]
Lu AF28996 DMY572G Parkinson disease 8A00.0 Phase 1 [27]
BAM-1110 DMPMKUF Parkinson disease 8A00.0 Discontinued in Phase 2 [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D4 receptor (D4R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clozapine DMFC71L Schizophrenia 6A20 Approved [5]
Phenyltoloxamine DMKAEQW Allergy 4A80-4A85 Approved [20]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [6]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [8]
L-745,870 DMTGR25 Psychotic disorder 6A20-6A25 Phase 2 [29]
NGD 94-1 DMM1Y8F Schizophrenia 6A20 Phase 1 [30]
ABT-724 DMDQVY4 Erectile dysfunction HA01.1 Discontinued in Phase 2 [31]
Lu-35138 DMQ7A35 Psychotic disorder 6A20-6A25 Discontinued in Phase 2 [32]
NGD-94-4 DMZ9WLO Schizophrenia 6A20 Discontinued in Phase 1 [33]
PD-165167 DMD0GB4 Schizophrenia 6A20 Preclinical [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [34]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [35]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [36]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [4]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [37]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [38]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [39]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [40]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [41]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D2 receptor (D2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [42]
Haloperidol DM96SE0 Delirium Approved [43]
Perphenazine DMA4MRX Schizophrenia 6A20 Approved [44]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [45]
Domperidone DMBDPY0 Gastrointestinal disease DE2Z Approved [46]
Levodopa DMN3E57 Parkinson disease 8A00.0 Approved [47]
Quetiapine DM1N62C Anorexia nervosa cachexia 6B80 Approved [48]
Pimozide DMW83TP Schizophrenia 6A20 Approved [49]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [50]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [36]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [5]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [51]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [52]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [53]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [4]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [54]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [55]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [56]
Treximet DMU54QB Migraine 8A80 Approved [11]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 7 receptor (HTR7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [8]
JNJ-18038683 DMV1T59 Major depressive disorder 6A70.3 Phase 2 [57]
AVN-101 DMOGFNI Cognitive impairment 6D71 Phase 2 [58]
ATI-9242 DM6GKMU Schizophrenia 6A20 Phase 1 [59]
PMID30124346-Compound-34TABLE4 DM2G3VE Attention deficit hyperactivity disorder 6A05.Z Patented [60]
PMID30124346-Compound-13TABLE4 DMHTJVA Attention deficit hyperactivity disorder 6A05.Z Patented [60]
Carbamide derivative 2 DMW5GI3 N. A. N. A. Patented [61]
4-oxadiazole derivative 1 DMWFHKR N. A. N. A. Patented [61]
SB-269970 DM8WTGA Sleep-wake disorder 7A00-7B2Z Terminated [62]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2C receptor (HTR2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [34]
Lorcaserin DMG6OYJ Obesity 5B81 Approved [64]
Tramadol DMRQD04 Osteoarthritis FA00-FA05 Approved [65]
Mirtazapine DML53ZJ Depression 6A70-6A7Z Approved [66]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [67]
Methysergide DM1EF73 Migraine 8A80 Approved [68]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [69]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [70]
SR46349B DM1ODMR Primary insomnia 7A00 Phase 3 [71]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [72]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Inhibitor [2]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [2]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Inhibitor [2]
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Inhibitor [3]
5-HT 7 receptor (HTR7) TTO9X1H 5HT7R_HUMAN Inhibitor [2]
Dopamine D1 receptor (D1R) TTZFYLI DRD1_HUMAN Inhibitor [2]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Inhibitor [2]
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Inhibitor [2]
Dopamine D4 receptor (D4R) TTE0A2F DRD4_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 276).
2 Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
3 Synthesis and SAR of tolylamine 5-HT6 antagonists. Bioorg Med Chem Lett. 2009 May 1;19(9):2409-12.
4 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
7 Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
11 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
12 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
13 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
14 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
15 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
16 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
17 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
18 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
19 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
20 Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
21 Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
22 Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
23 Clinical pipeline report, company report or official report of Lundbeck.
24 A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
25 Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
26 trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
27 Clinical pipeline report, company report or official report of Lundbeck
28 Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
29 Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
30 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
31 Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
32 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
33 I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.
34 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
35 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
36 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
37 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
38 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
39 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
40 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
41 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
42 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
43 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
44 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
45 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
46 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
47 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
48 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
49 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
50 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
51 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
52 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
53 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
54 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
55 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
56 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
57 Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
58 AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
59 Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
60 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
61 Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
62 [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
63 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
64 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
65 The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
66 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
67 Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
68 Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
69 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
70 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
71 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
72 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.